India, March 8 -- Eli Lilly and Co. (LLY) and Incyte's (INCY) late-breaking results from Phase 3 BRAVE-AA-PEDS study found adolescent patients (ages 12 to under 18) with severe alopecia areata treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36. The study results were presented in a late-breaker presentation at the American Academy of Dermatology (AAD) Annual Meeting taking place March 7-11 in Orlando.
Alopecia areata or AA is an immune system condition that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress over time. Approximately 40% of patients with AA experience first onset by 2...